Klug Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 02-07-2024
- Paid Up Capital ₹ 0.10 M
as on 02-07-2024
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 0.90 M
as on 02-07-2024
- Revenue 2.24%
(FY 2020)
- Profit -2693.98%
(FY 2020)
- Ebitda -96.51%
(FY 2020)
- Net Worth -24.71%
(FY 2020)
- Total Assets 2.44%
(FY 2020)
About Klug Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹0.90 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ritvik Chaturvedi and Saatvik Chaturvedi serve as directors at the Company.
- CIN/LLPIN
U24232RJ2014PTC045576
- Company No.
045576
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 May 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Klug Pharmaceuticals Private Limited offer?
Klug Pharmaceuticals Private Limited offers a wide range of products and services, including Medical Surgery & Treatment Centres, Medical Treatment Services.
Who are the key members and board of directors at Klug Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saatvik Chaturvedi  | Director | 29-Jun-2015 | Current |
| Ritvik Chaturvedi | Director | 30-Mar-2023 | Current |
Financial Performance of Klug Pharmaceuticals.
Klug Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 2.24% increase. The company also saw a substantial fall in profitability, with a 2693.98% decrease in profit. The company's net worth observed a substantial decline by a decrease of 24.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Klug Pharmaceuticals?
In 2019, Klug Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Jan 2018 | ₹0.90 M | Satisfied |
How Many Employees Work at Klug Pharmaceuticals?
Unlock and access historical data on people associated with Klug Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Klug Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Klug Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
